192 related articles for article (PubMed ID: 35725413)
1. The feasibility of proteomics sequencing based immune-related prognostic signature for predicting clinical outcomes of bladder cancer patients.
Jiang L; Chen S; Pan Q; Zheng J; He J; Sun J; Han Y; Yang J; Zhang N; Fu G; Gao F
BMC Cancer; 2022 Jun; 22(1):676. PubMed ID: 35725413
[TBL] [Abstract][Full Text] [Related]
2. Construction of an Immune-Associated Gene-Based Signature in Muscle-Invasive Bladder Cancer.
Shen C; Xu T; Sun Y; Wang L; Liang Z; Niu H; Jiao W; Wang Y
Dis Markers; 2020; 2020():8866730. PubMed ID: 33456631
[TBL] [Abstract][Full Text] [Related]
3. A novel signature constructed by differential genes of muscle-invasive and non-muscle-invasive bladder cancer for the prediction of prognosis in bladder cancer.
Wang W; Zhang X; Jiang S; Xu P; Chen K; Li K; Wang F; Le X; Zhang K
Front Immunol; 2023; 14():1187286. PubMed ID: 37691944
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitination-Related Molecular Subtypes and a Novel Prognostic Index for Bladder Cancer Patients.
Cai H; Chen H; Huang Q; Zhu JM; Ke ZB; Lin YZ; Zheng QS; Wei Y; Xu N; Xue XY
Pathol Oncol Res; 2021; 27():1609941. PubMed ID: 34776794
[No Abstract] [Full Text] [Related]
5. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
Jiang W; Zhu D; Wang C; Zhu Y
Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
[TBL] [Abstract][Full Text] [Related]
6. Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks.
Xu Y; Sun X; Liu G; Li H; Yu M; Zhu Y
Front Immunol; 2023; 14():1301157. PubMed ID: 38299148
[TBL] [Abstract][Full Text] [Related]
7. Cytoskeleton regulator RNA expression on cancer-associated fibroblasts is associated with prognosis and immunotherapy response in bladder cancer.
Wu Y; Xu Y; He S; Li Y; Feng N; Fan J; Gong Y; Li X; Zhou L
Heliyon; 2023 Mar; 9(3):e13707. PubMed ID: 36873531
[TBL] [Abstract][Full Text] [Related]
8. Identification of Prognosis-Related Genes in Bladder Cancer Microenvironment across TCGA Database.
Zhao X; Tang Y; Ren H; Lei Y
Biomed Res Int; 2020; 2020():9143695. PubMed ID: 33204728
[TBL] [Abstract][Full Text] [Related]
9. Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer.
Sun X; Xin S; Jin L; Zhang Y; Ye L
Bioengineered; 2022 May; 13(5):13986-13999. PubMed ID: 35758021
[TBL] [Abstract][Full Text] [Related]
10. Multi-omics reveals novel prognostic implication of SRC protein expression in bladder cancer and its correlation with immunotherapy response.
Xu W; Anwaier A; Ma C; Liu W; Tian X; Palihati M; Hu X; Qu Y; Zhang H; Ye D
Ann Med; 2021 Dec; 53(1):596-610. PubMed ID: 33830879
[TBL] [Abstract][Full Text] [Related]
11. A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer.
Sun JX; Liu CQ; Xu JZ; An Y; Xu MY; Zhong XY; Zeng N; Ma SY; He HD; Zhang ZB; Wang SG; Xia QD
Front Immunol; 2022; 13():908068. PubMed ID: 35898492
[TBL] [Abstract][Full Text] [Related]
12. Construction and verification of a prognostic risk model based on immunogenomic landscape analysis of bladder caner.
Zhang Y; Xie Y; Feng Y; Wang Y; Xu X; Zhu S; Xu F; Feng N
Gene; 2022 Jan; 808():145966. PubMed ID: 34530089
[TBL] [Abstract][Full Text] [Related]
13. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of a prognostic immune-related lncRNA signature in bladder cancer.
Zhao K; Zhang Q; Zeng T; Zhang J; Song N; Wang Z
Transl Androl Urol; 2021 Mar; 10(3):1229-1240. PubMed ID: 33850758
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin
Zhou Q; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Liu L; Zhu Y; Xu L; Dai B; Guo J; Xia Y; Wang Y; Xu J
Oncoimmunology; 2020 Apr; 9(1):1747333. PubMed ID: 33457092
[TBL] [Abstract][Full Text] [Related]
16. Can uric acid affect the immune microenvironment in bladder cancer? A single-center multi-omics study.
Chen H; Shi D; Guo C; Zhang W; Guo Y; Yang F; Wang R; Zhang J; Fang Z; Yan Y; Mao S; Yao X
Mol Carcinog; 2024 Mar; 63(3):461-478. PubMed ID: 38018692
[TBL] [Abstract][Full Text] [Related]
17. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
[TBL] [Abstract][Full Text] [Related]
19. Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer.
Wang Y; Chen L; Yu M; Fang Y; Qian K; Wang G; Ju L; Xiao Y; Wang X
Cancer Med; 2020 Oct; 9(20):7729-7741. PubMed ID: 32841548
[TBL] [Abstract][Full Text] [Related]
20. Construction and validation of a metabolism-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer.
Shen C; Bi Y; Chai W; Zhang Z; Yang S; Liu Y; Wu Z; Peng F; Fan Z; Hu H
BMC Med Genomics; 2023 Oct; 16(1):264. PubMed ID: 37880682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
